6.24
1.13%
+0.07
Overview
News
Price History
Option Chain
Financials
Why BHC Down?
Discussions
Forecast
Stock Split
Dividend History
Bausch Health Companies Inc stock is currently priced at $6.24, with a 24-hour trading volume of 961.52K.
It has seen a +1.13% increased in the last 24 hours and a -12.36% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.24 pivot point. If it approaches the $6.31 resistance level, significant changes may occur.
Previous Close:
$6.17
Open:
$6.11
24h Volume:
961.52K
Market Cap:
$2.29B
Revenue:
$8.76B
Net Income/Loss:
$-592.00M
P/E Ratio:
-2.3636
EPS:
-2.64
Net Cash Flow:
$760.00M
1W Performance:
-0.48%
1M Performance:
-12.36%
6M Performance:
-16.47%
1Y Performance:
-14.75%
Bausch Health Companies Inc Stock (BHC) Company Profile
Name
Bausch Health Companies Inc
Sector
Phone
514-744-6792
Address
2150 St. Elzéar Boulevard West, Laval, QC
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-20-23 | Upgrade | Jefferies | Hold → Buy |
Jun-16-23 | Downgrade | TD Cowen | Outperform → Market Perform |
Jul-29-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Jul-29-22 | Downgrade | Truist | Buy → Hold |
Jul-28-22 | Downgrade | JP Morgan | Overweight → Neutral |
Jun-13-22 | Resumed | JP Morgan | Overweight |
Mar-24-21 | Downgrade | BofA Securities | Neutral → Underperform |
Feb-17-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Jan-22-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Sep-17-20 | Upgrade | BofA Securities | Underperform → Neutral |
Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
Apr-24-20 | Initiated | Citigroup | Buy |
Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jan-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Jan-22-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Dec-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-02-19 | Initiated | Goldman | Neutral |
Oct-25-19 | Initiated | Cowen | Outperform |
Sep-12-19 | Initiated | Guggenheim | Buy |
Aug-15-19 | Upgrade | TD Securities | Hold → Buy |
Jul-19-19 | Initiated | Wolfe Research | Outperform |
Jun-11-19 | Resumed | Barclays | Overweight |
May-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
Mar-20-19 | Initiated | SunTrust | Buy |
Jan-02-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
Nov-05-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-13-18 | Upgrade | Piper Jaffray | Underweight → Neutral |
View All
Bausch Health Companies Inc Stock (BHC) Latest News
Closing Bell: Bausch Health Companies Inc down on Thursday (BHC) - The Globe and Mail
The Globe and Mail
Bausch Health Cos. Inc. stock falls Thursday, underperforms market - MarketWatch
MarketWatch
Closing Bell: Bausch Health Companies Inc up on Wednesday (BHC) - The Globe and Mail
The Globe and Mail
Bausch Health Cos. Inc. stock rises Wednesday, outperforms market - MarketWatch
MarketWatch
Should investors be concerned about BHC's high price-to-sales ratio? – US Post News - US Post News
US Post News
BHC’s Market Whiplash: -22.38% YTD Decline, -12.69% Plunge in 30 Days - The InvestChronicle
The InvestChronicle
Bausch Health Companies Inc Stock (BHC) Financials Data
Bausch Health Companies Inc (BHC) Revenue 2024
BHC reported a revenue (TTM) of $8.76 billion for the quarter ending December 31, 2023, a +7.79% rise year-over-year.
Bausch Health Companies Inc (BHC) Net Income 2024
BHC net income (TTM) was -$592.00 million for the quarter ending December 31, 2023, a -163.11% decrease year-over-year.
Bausch Health Companies Inc (BHC) Cash Flow 2024
BHC recorded a free cash flow (TTM) of $760.00 million for the quarter ending December 31, 2023, a +176.31% increase year-over-year.
Bausch Health Companies Inc (BHC) Earnings per Share 2024
BHC earnings per share (TTM) was -$1.62 for the quarter ending December 31, 2023, a -161.29% decline year-over-year.
About Bausch Health Companies Inc
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal. The company also develops and markets products that treat gastrointestinal and hepatologic conditions comprising hepatic encephalopathy, irritable bowel syndrome with diarrhea, traveler's diarrhea, opioid-induced constipation, ulcerative colitis, and others. In addition, it offers eye health products, such as contact lens; products that treat various eye conditions, including glaucoma, eye allergies, conjunctivitis, dry eye, and retinal diseases; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for the treatment of cataracts, and vitreous and retinal eye conditions. Further, the company provides products in the therapeutic areas of epilepsy, migraines, depression, chronic pain, and rare diseases such, as huntington's disease; and oral health products for adult periodontitis and mouth dryness, as well as teeth-whitening. Additionally, it offers eye drops; skin care products, including moisturizers; and eye vitamins and mineral supplements, as well as neurology products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.
Cap:
|
Volume (24h):